Drug Trial Radar · NCT07702032
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
960
Planned (sponsor's estimate)
Start
Aug 11, 2026
Primary completion
Jul 2029
Study completion Sep 2031
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other parts of the body. Participants will receive either petosemtamab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI) or standard-of-care cetuximab + doctor's choice of chemotherapy (mFOLFOX6 or FOLFIRI). No participants will be given placebo. The treatment duration will be different for every participant. If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participants will be asked to attend 2 visits at the study clinic for each cycle (duration of cycle is 4 weeks). During visits, there will be various tests (such as blood draws) and procedures (such as imaging) to monitor whether the study treatment is safe and effective. The overall study duration (including screening, treatment, and follow-up) will be different for every participant.
Conditions
- Left-sided Colorectal Cancer
Interventions
PetosemtamabDrug
Intravenous infusion
CetuximabDrug
Intravenous infusion
FOLFIRIDrug
Fluorouracil + leucovorin (calcium folinate) + irinotecan via intravenous infusion.
mFOLFOX6Drug
Fluorouracil + leucovorin (calcium folinate) + oxaliplatin via intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 35 months
- Objective Response Rate (ORR) per RECIST v1.1 as Assessed by BICRTime frame: Up to approximately 35 months
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
Genesis Cancer Center
Hot Springs, Arkansas · Recruiting
Valkyrie Clinical Trials - Los Angeles
Los Angeles, California · Recruiting
Low Country Cancer Care Associates_Savannah_1
Savannah, Georgia · Recruiting
Central Georgia Cancer Care - Warner Robins Office
Warner Robins, Georgia · Recruiting
Hematology-Oncology of Indiana, P.C.
Indianapolis, Indiana · Recruiting
Oncology Hematology Associates - Springfield_Springfield_2
Springfield, Missouri · Recruiting
Washington University Saint Louis
St Louis, Missouri · Recruiting
New York Cancer and Blood Specialists - Babylon Medical Oncology
Babylon, New York · Recruiting
Vista Oncology
Olympia, Washington · Recruiting
GenesisCare - Campbelltown CAMPBELLTOWN
Campbelltown, New South Wales, Australia · Recruiting
GenesisCare - St Andrew's ADELAIDE
Adelaide, South Australia, Australia · Recruiting
PanOncology
Manati, PR, Puerto Rico · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.